Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
Abstract: Therapeutic methods and pharmaceutical compositions for treating splenomegaly in a human subject are described. In certain embodiments, the invention includes therapeutic methods of treating splenomegaly using a BTK inhibitor.
Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.
Abstract: An iron/shikonin nano-composite and a use thereof, and a method for preparing the same by supermolecular self-assembly, belonging to the technical field of functional materials. The composite consists of shikonin and ferric ions, wherein shikonin is coordinated with the ferric ions, and the hydroxyl and carbonyl groups in shikonin are coordinated with the ferric irons to form a complex, which is then assembled by ?-? stacking and hydrophobic interactions to form a nano-composite which exhibits glutathione response. The composite is obtained by the following steps: adding an aqueous solution of a ferric salt and an organic solvent solution of shikonin in sequence into water while stirring at ambient temperature, continuously stirring at ambient temperature, and centrifuging the resulting mixture to purify, thereby obtaining an iron/shikonin nano-composite in the resulting solution.
Type:
Grant
Filed:
June 1, 2021
Date of Patent:
May 2, 2023
Assignee:
Jilin University
Inventors:
Hao Zhang, Wenjie Feng, Yi Liu, Lening Zhang, Wanrui Shi
Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
Type:
Grant
Filed:
June 23, 2021
Date of Patent:
April 25, 2023
Assignee:
Celgene Corporation
Inventors:
Matthew D. Alexander, Matthew D. Correa, Deepak Dalvie, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, III, Evan J. Horn, Dehua Huang, Christopher Mayne, Stephen Norris, Veronique Plantevin-Krenitsky, John J. Sapienza, Lida Tehrani, Brandon W. Whitefield
Abstract: The present invention is concerned with novel deuterated Angiotensin-Converting Enzyme-2 (ACE-2) inhibitors of general structural formula I, their optically active enantiomers and diastereoisomers, and pharmaceutical salts and compositions thereof, as well as combination therapies which include compounds of the present invention, These compounds have high potency and selectivity for Angiotensin-Converting Enzyme-2 (ACE-2) inhibition, and are useful in the treatment of infectious respiratory diseases including the pandemic disease Covid-19, Severe Acute Respiratory Syndrome (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS-CoV), and other diseases caused by coronaviruses.
Abstract: This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.
Abstract: The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation.
Type:
Grant
Filed:
November 6, 2018
Date of Patent:
April 18, 2023
Assignee:
JUBILANT PRODELL LLC
Inventors:
Chandregowda Venkateshappa, Athisayamani Jeyaraj Duraiswamy, Rama Kishore V P Putta, Sridharan Rajagopal
Abstract: The present invention relates to a compound isolated from Torilidis Fructus, and an anticancer pharmaceutical composition containing same as an active ingredient, wherein the compound of the present invention has effects of reducing the viability of various types of cancer cells, having no effect on the cell viability of normal cells and reducing the tumor size and weight of lung cancer and colorectal cancer when used in an animal model. Therefore, the compound according to the present invention can be usefully used in anticancer drugs or health functional food industries.
Abstract: The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.
Abstract: The present invention provides solid state forms of Venetoclax, particularly relates to novel alkali metal salt and/or DMF solvate form of Venetoclax or its salt. The present invention also relates to process for the preparation Venetoclax by using the said solid state form of Venetoclax.
Abstract: The present disclosure belongs to the field of medicines, and particularly relates to property researches of an indotricarbocyanine structure-based small molecule medicine for tumor photothermal therapy. The present disclosure is based on a large-conjugated water-soluble indotricarbocyanine dye compound developed by the applicant, and the compound can be used as a photothermal therapeutic agent, and has a potential development and application prospect. In the present disclosure, the compound is found to be an excellent tumor photothermal therapy medicine, and such use of this compound has not been found and reported at present. Through in-vitro property researches on the photothermal efficiency of this compound, a foundation is provided for clinical application of the indocyanine green-like small molecule photothermal therapeutic agent, and a basis is provided for researches of the small molecule photothermal therapeutic agent.
Type:
Grant
Filed:
May 31, 2022
Date of Patent:
March 28, 2023
Assignee:
Nanjing Nuoyuan Medical Devices Co., LTD.
Abstract: Compositions and methods for treating and preventing respiratory symptoms related to viral and bacterial infections are described. The composition includes water, ionic minerals, trace minerals, a niacin-related compound, and an optional ingredient. The optional ingredient is mastic gum, a prebiotic, or both. The niacin-related compound is methyl nicotinate, nicotinic acid, nicotinamide, niacin, or a combination of two or more of the foregoing. The method involves nasal, auricular, or oral administration or a combination of two or more of the foregoing routes of administration to a human or other mammal.
Abstract: A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.
Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.
Abstract: Crystalline polymorph forms of neurotrophic agent 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide (J147), and process for producing the crystalline polymorphic form are provided.
Type:
Grant
Filed:
January 17, 2021
Date of Patent:
February 21, 2023
Assignee:
ABREXA PHARMACEUTICALS, INC.
Inventors:
Michael O'Neill, Barbara Kidon, William A. Janz, Hongqiao Wu
Abstract: The present invention relates to a non-hygroscopic salt of the compound 2-(3-(4-propylheptyl)morpholino)ethan-1-ol having the INN name delmopinol. In particular, the invention relates to the citrate salt of delmopinol. The present invention also relates to pharmaceutical compositions comprising the citrate salt of delmopinol depicted below.
Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
February 14, 2023
Assignee:
AVIDITY BIOSCIENCES, INC.
Inventors:
Venkata Ramana Doppalapudi, Michael Caramian Cochran, David Sai-Ho Chu, Joel Daniel Arias, Rob Burke
Abstract: Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.
Type:
Grant
Filed:
June 6, 2022
Date of Patent:
February 7, 2023
Assignee:
MODRA PHARMACEUTICALS B.V.
Inventors:
Jacob Hendrik Beijnen, Johannes Henricus Schellens